Scinai Immunotherapeutics Ltd. (SCNI) Cash Flow Statement

The significant gap between net income and operating cash flow suggests that reported earnings are heavily influenced by non-cash items or accounting adjustments rather than operational success. Investors should monitor this divergence closely, as it indicates that the company's core business activities remain fundamentally cash-consumptive despite occasional positive net income figures.

The consistent negative FCF trajectory suggests that the company is trapped in a cycle of capital expenditure and operating losses that cannot be offset by its current service-based revenue model. This trend warrants further investigation into how long the company can sustain operations without recurring to dilutive financing.

This volatility in working capital management appears to exacerbate the company's already strained liquidity position. The inability to maintain a stable working capital cycle may indicate operational inefficiencies in managing service contracts or a reliance on irregular cash inflows to meet short-term obligations.

The decision to deploy capital toward share repurchases while simultaneously burning cash from operations may suggest a misalignment between capital allocation strategy and the company's actual financial health. Investors should monitor whether future capital is prioritized for essential R&D milestones rather than non-essential balance sheet management.